Since the III. Breast Cancer Consensus Conference, a number of new evidence based
on clinical trial results have been published which justified updating the 2016 recommendation.
In addition to classical prognostic factors, some multigenic tests, which we have
incorporated into the recommendation, will play an important role in therapeutic decision-making.
The professional guide primarily reflects the resolutions and recommendations of the
current ESMO, NCCN, ABC4, as well as the St. Gallen Consensus Conference. From a didactic
point of view, the text follows first the line of early and then locally advanced
breast cancer, locoregionally recurrent and metastatic breast cancer. Within these,
we discuss each group according to therapeutic options.
